Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy
- Authors
- Lee, Hyun Woong; Chang, Hye Young; Yang, Suh Yoon; Kim, Hyung Joon
- Issue Date
- Jul-2014
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Tenofovir; Chronic hepatitis B; Resistance; Mutation
- Citation
- JOURNAL OF CLINICAL VIROLOGY, v.60, no.3, pp 313 - 316
- Pages
- 4
- Journal Title
- JOURNAL OF CLINICAL VIROLOGY
- Volume
- 60
- Number
- 3
- Start Page
- 313
- End Page
- 316
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12084
- DOI
- 10.1016/j.jcv.2014.03.018
- ISSN
- 1386-6532
1873-5967
- Abstract
- A 54-year-old man diagnosed with HBeAg-positive chronic hepatitis B (CHB) was treated with entecavir (ETV) 1 mg/day following an initial unsuccessful lamivudine (LAM) treatment (rtL180M, rtM204V/I). Subsequently, virological breakthrough with ETV mutation (rtT184A/L) developed. The LAM and adefovir combination therapy was followed by virological breakthrough. The therapy had been switched to TDF monotherapy. However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rt5223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation. TDF resistance may emerge due to multi-site polymerase mutations rather than single-site polymerase mutation. (C) 2014 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.